New Rochelle, NY, December 9, 2016--Recent evidence from animal models suggests a role for specific types of intestinal bacteria in the development of colorectal cancer (CRC). If a microbial imbalance in the gut could actively contribute to CRC in humans, dietary-based therapeutic interventions may be able to modify the composition of the gut microbiome to reduce CRC risk, as discussed in a review article published in BioResearch Open Access, a peer-reviewed open access journal from Mary Ann Liebert, Inc., publishers. The article is available free on the BioResearch Open Access website.
Olivia Coleman and Tiago Nunes, Technical University of Munich (Freising-Weihenstephan, Germany), discuss the significance and therapeutic implications of the latest evidence linking the intestinal microbiota to CRC development and progression. In the article entitled "Role of the Microbiota in Colorectal Cancer: Updates on Microbial Associations with CRC and Therapeutic Implications," the authors highlight the protective effects that probiotics and prebiotics can have against CRC through their ability to modulate the gut microbiome and, specifically, to expand the population of lactic acid-producing bacteria.
"This review provides an excellent overview of the relationship between the intestinal microbiota and colorectal cancer development. Potential therapies and preventative strategies are also discussed," says BioResearch Open Access Editor Jane Taylor, PhD, Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, Scotland.
About the Journal
BioResearch Open Access (http://www.liebertpub.com/biores) is a peer-reviewed open access journal led by Editor-in-Chief Robert Lanza, MD, Head of Astellas Global Regenerative Medicine and Chief Scientific Officer, Astellas Institute for Regenerative Medicine (Marlborough, MA), and Editor Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh. The Journal provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMed Central. All journal content is available on the BioResearch Open Access (http://www.liebertpub.com/biores) website.
About the Publisher
Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com/) is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many areas of science and biomedical research, including DNA and Cell Biology, Tissue Engineering, Stem Cells and Development, Human Gene Therapy, HGT Methods, and HGT Clinical Development, and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com/) website.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.